<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In the present studies, we have examined the effects of two new Ca(2+) channel blockers, LY042826 (N-[2-[(<z:chebi fb="0" ids="52554">2-methylphenyl</z:chebi>)(<z:chebi fb="1" ids="30396">phenyl</z:chebi>)<z:chebi fb="8" ids="32772">methoxy</z:chebi>]ethyl]-1-<z:chebi fb="0" ids="43799">butanamine</z:chebi> <z:chebi fb="16" ids="36807">hydrochloride</z:chebi>) and LY393615 (N-[[5, 5-bis(4-fluorophenyl)tetrahydro-2-<z:chebi fb="0" ids="24131">furanyl</z:chebi>]<z:chebi fb="36" ids="29309">methyl</z:chebi>]-1-<z:chebi fb="0" ids="43799">butanamine</z:chebi> <z:chebi fb="16" ids="36807">hydrochloride</z:chebi>) in the gerbil model of global and the endothelin-1 rat model of focal <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> in vivo </plain></SENT>
<SENT sid="1" pm="."><plain>Results indicated that both LY042826 (P&lt;0.01) and LY393615 (P&lt;0.001) provided significant protection against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-induced hippocampal damage in global <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> when dosed at 15 mg/kg i.p </plain></SENT>
<SENT sid="2" pm="."><plain>30 min before and 2 h 30 min after occlusion </plain></SENT>
<SENT sid="3" pm="."><plain>In further studies, LY042826 (P&lt;0.05) and LY393615 (P&lt;0.01) were also protective when administered at 15 mg/kg i.p. immediately after and 3 h post-occlusion </plain></SENT>
<SENT sid="4" pm="."><plain>Both compounds also provided a significant reduction in the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume following endothelin-1 middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in the rat when administered at 15 mg/kg i.p. immediately (P&lt;0.05) after occlusion </plain></SENT>
<SENT sid="5" pm="."><plain>This protection was similar to that observed with the <z:chebi fb="0" ids="31882">NMDA</z:chebi> receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> (5R,10S)-(+)-5-<z:chebi fb="36" ids="29309">methyl</z:chebi>-10, 11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-<z:chebi fb="0" ids="24783">imine</z:chebi>), MK-801 in this model </plain></SENT>
<SENT sid="6" pm="."><plain>In conclusion and as a result of the present studies, we report that the novel Ca(2+) channel blockers, LY042826 and LY393615 protect against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-induced brain injury in gerbils and rats </plain></SENT>
<SENT sid="7" pm="."><plain>The compounds were neuroprotective when administered post-occlusion and may therefore be useful anti-ischaemic agents </plain></SENT>
</text></document>